openPR Logo
Press release

Advancements in technologies have enabled Bio-Synthesis to expand their product line to include Long Oligo Synthesis

05-03-2012 10:39 AM CET | Science & Education

Press release from: Bio-Synthesis, Inc.

Bio-Synthesis offers long oligo synthesis and gene synthesis services as control templates, cloning, mutagenesis, gene expression and other demanding applications. BSI has provided thousands of high-fidelity synthesis of very long oligos, DNA UbermersTM, with impeccable quality and services which are unmatched by other suppliers.

Longer constructs that required more choices like palindromes for restriction enzymes give researchers more flexibility. DNA UbermersTM are also used as an internal control template with or without certain SNP's and have been use in amplification reactions like Real-Time PCR and qPCR. All Oligo UbermersTM are delivered deprotected, desalted to remove small molecular impurities, and PAGE purified for extremely high purity needs. For even greater convenience, all Oligo UbermersTM are delivered lyophilized.

While there has been significant demand for long oligos, the yields in conventional DNA synthesis and the associated side reactions have been previously limited due to the length. Bio-Synthesis's expertise in artificial gene synthesis and microarray development provides the ability to synthesize thousands of single strand synthetic long DNA oligos using the best DNA synthesis reagents available. Optimized long oligo synthesis protocols permit high quality DNA oligomer with superior coupling efficiency through an entire DNA synthesis reaction. Each long custom DNA oligo is meticulously monitored during synthesis and controlled according to Bio-Synthesis’s stringent quality assurance and quality control standards.

As the capabilities of RNA analysis expand, the need to obtain a standardized RNA fragment has become increasingly important in the development of molecular diagnostic techniques. RNA oligos can be added and quantified at will, making them very important as reliable controls for each step of the RT-PCR protocol to ensure the accuracies of diagnostic test results. Many RNA based applications not only uses short RNA but very long RNA sequences. The typical RNA control fragment for RT-PCR, Spike-in control or transcript/mRNA for protein synthesis, require RNA fragments between 200 bases and a few thousand bases. Bio-Synthesis is uniquely positioned and capable to synthesizing long RNA fragment with greater length, quality and fast turnaround time.

About Bio-Synthesis

Bio-Synthesis is a manufacturer of custom peptide synthesis, antibodies, bioconjugates, DNA, RNA, PNA, organic synthesis, microarrays, gene synthesis, cloning, detection kits, cell line authentication, and a diverse number of bimolecular products for the biomedical/life science community worldwide.

With over 27 years of experience producing custom products for both research and pharmaceutical use, BSI has developed a reputation for both small and large scale synthesis using optimal processes that meet your specifications. BSI is a U.S. based company, therefore all products are exclusively manufactured at the state-of-the-art facilities in Lewisville, Texas.

Bio-Synthesis, Inc.
612 East Main Street
Lewisville, TX 75057

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Advancements in technologies have enabled Bio-Synthesis to expand their product line to include Long Oligo Synthesis here

News-ID: 219763 • Views: 2896

More Releases for RNA

Global RNA Analysis/Transcriptomics Market Report
The Global RNA Analysis / Transcriptomics Market is projected to expand at a CAGR of 12.5% during the forecast period, to hit USD 8.1 Billion by 2026, according to a recent market report compiled by Global Market Estimates. Due to the rising need for personalized medicines, the demand for RNA Analysis / Transcriptomics is expected to raise the market demand. Browse 156 Market Data Tables and 112 Figures spread through 175
Cancer RNA Expression Market to Reap Excessive Revenues by 2028(By sequencing te …
Worldwide cancer is one of the leading cause of death and effective way of treating it still looks unaccomplished in most parts of the world. The factors which influence the successful treatment of cancer are different depending on the stage of diagnosis, treatment availability and availability of trained healthcare professionals coupled with high economic burden of the disease. The gene expression of cancerous cells varies by cancer type and may
Senior experts from Exicure, Roche, GSK, BioNTech RNA Pharmaceuticals & MiNA The …
With less than 4 weeks until SMi’s 10th annual RNA Therapeutics event ( opens its doors in London, UK next month, registration will soon be closing and delegate places are becoming increasingly limited. Over the course of 2 focused days, attendees will be able to have an exclusive look into key developments in oligonucleotide therapeutics, mRNA technology, delivery mechanisms, and much more, led by industry leaders, scientific pioneers, and academics exploring
RNA Therapy Improves Vision in Child Blindness, hear more about recent developme …
SMi Reports: In light of recent developments in the field of RNA Therapy, SMi’s 10th Annual RNA Therapeutics is set to deliver the latest advancements in February this year. Leber congenital amaurosis (LCA), one of the most common causes of blindness in children, has been the subject of successful RNA therapy as researchers at the University of Pennsylvania recently published new data showing the success of the new therapy which improved
New Confirmed Delegates & Speakers for RNA Therapeutics
SMi are thrilled to welcome Dr. James Hamilton, Vice President, Head of Clinical Development, Arrowhead Pharmaceuticals onto the speaker panel RNA Therapeutics 2018! Dr. James Hamilton is currently responsible for all aspects of clinical trial design, implementation and execution. In this role, Dr. Hamilton managed the ARC-520 and ARC-AAT global programs through Phase 2 of development. Previously, Dr. Hamilton was Medical Director and Head of Corporate Development at Arrowhead. He led
Introducing the 9th Annual RNA Therapeutics 2018
As the requirement for targeted solutions for chronic diseases continues to grow, the interest of pharmaceutical and biotech companies has increasingly focused towards RNA therapeutics, such that by 2020, the RNA Therapeutics Market is predicted to attain $1.2 billion. One of the main challenges in RNA Therapeutics continues to be bridging the gap between in-vivo and in-vitro models, hear key case studies on the development on the latest delivery systems and